WO2025037286 - INTRAUTERINE FORMULATION CONTAINING HENNA EXTRACT
National phase entry is expected:
Publication Number
WO/2025/037286
Publication Date
20.02.2025
International Application No.
PCT/IB2024/058846
International Filing Date
11.09.2024
Title **
[English]
INTRAUTERINE FORMULATION CONTAINING HENNA EXTRACT
[French]
FORMULATION INTRA-UTÉRINE CONTENANT UN EXTRAIT DE HENNÉ
Applicants **
YOUSEFI, Gholamhossein
ROWSHANGHASRODASHTI, Abbas
MOKHTARZADEGAN, Mohammad
Inventors
YOUSEFI, Gholamhossein
ROWSHANGHASRODASHTI, Abbas
MOKHTARZADEGAN, Mohammad
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
IP India
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Natural Person
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| 译文 |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 1912 | |
| EPO | Filing, Examination, Granting | 8697 | |
| Japan | Filing, Examination, Granting | 2031 | |
| South Korea | Filing, Examination, Granting | 1779 | |
| USA | Filing, Examination, Granting | 8940 |
Total:
23,359
Contact Us
Abstract[English]
The present disclosure relates in certain aspects to specific organic compounds useful, including henna extract, for the treatment, amelioration and/or prevention of fungal infections in animals. This disclosure further relates in certain aspects to certain useful compositions centered on henna extract for the treatment of infection in female livestock. This invention is superior to existing standard treatments in terms of effectiveness and non-recurrence of infection, and it does not have serious side effects, microbial resistance and subsequent problems, including the presence of residues in meat and milk. The statistical results in figure1 show the effect of the formulation containing henna extract on the rate of infection compared to cefapim.[French]
La présente divulgation concerne, dans certains aspects, des composés organiques spécifiques utiles, notamment un extrait de henné, pour le traitement, l'amélioration et/ou la prévention d'infections fongiques chez des animaux. La présente divulgation concerne en outre certains aspects de certaines compositions utiles centrées sur un extrait de henné pour le traitement d'une infection chez le bétail femelle. La présente invention est supérieure aux traitements classiques existants en termes d'efficacité et de non récurrence d'infection, et elle ne présente ni effets secondaires graves, ni résistance microbienne et ni problèmes ultérieurs, notamment la présence de résidus dans la viande et le lait. Les résultats statistiques de la figure 1 montrent l'effet de la formulation contenant un extrait de henné sur le taux d'infection par rapport au cefapim.